Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

INTRODUCTION: Therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) patients are continuously advancing. We described mCRPC treatment patterns in the US from 2013 to 2019. METHODS: Patients with a confirmed mCRPC diagnosis and adenocarcinoma histology were included in the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal D., Laliberté, François, Ionescu-Ittu, Raluca, Yang, Lingfeng, Mahendran, Malena, Lejeune, Dominique, Yu, Louise H., Burgents, Joseph, Duh, Mei Sheng, Ghate, Sameer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342357/
https://www.ncbi.nlm.nih.gov/pubmed/34282527
http://dx.doi.org/10.1007/s12325-021-01823-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342357/
https://www.ncbi.nlm.nih.gov/pubmed/34282527
http://dx.doi.org/10.1007/s12325-021-01823-6

Ejemplares similares